SCHEMBL1768175

SCHEMBL1768175

Cc1cc(C)c(-c2c(C)cc(C)c(C)c2P(c2ccccc2)c2ccccc2)c(P(c2ccccc2)c2ccccc2)c1C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 3/20 0.35
POLB P06746 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007683 0.77 CYP3A4 (0.48) CYP3A4TDP1ALDH1A1POLBKDM4E
SCHEMBL7134044 0.76 CYP3A4 (0.42) CYP3A4TDP1ALDH1A1POLBMEN1
SCHEMBL17426096 0.76 CYP3A4 (0.38) CYP3A4TDP1ESR1ESR2
SCHEMBL7999830 0.72 TDP1 (0.48) CYP3A4TDP1ALDH1A1POLBMEN1
SCHEMBL12446368 0.72 CYP3A4 (0.42) CYP3A4TDP1ALDH1A1POLBMEN1
SCHEMBL29597288 0.72 CYP3A4 (0.42) CYP3A4TDP1ALDH1A1POLBMEN1
SCHEMBL1403691 0.72 CYP3A4 (0.42) CYP3A4TDP1ALDH1A1POLBKDM4E
SCHEMBL1011883 0.72 TDP1 (0.52) CYP3A4TDP1ALDH1A1KDM4EESR1
SCHEMBL12601255 0.69 CYP3A4 (0.39) CYP3A4TDP1ALDH1A1RAB9AESR1
SCHEMBL12889878 0.68 CYP3A4 (0.48) CYP3A4TDP1KDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935827-B2 Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters BAYER SCHERING PHARMA AG (DE) 2011-05-03 US disclosed
US-20100248313-A1 NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS BAYER SCHERING PHARMA AG (DE) 2010-09-30 US disclosed
US-7626035-B2 Ethyl 2-(benzothiazol-2-yl),2-oxo-acetate; useful in the synthesis of epothilonederivatives; antitumor,-carcinogenic agents; high chemical purity, optical purity,in very good yields and allows an industrial-scale production BAYER SCHERING PHARMA AG (DE) 2009-12-01 US disclosed
EP-2113031-A1 OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS, PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-11-04 EP disclosed
EP-1863780-A1 PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN Pharmacia & Upjohn Company LLC (US) 2007-12-12 EP disclosed
WO-2006100568-A1 PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
US-20060148043-A1 Novel optically active, heteroaromatic beta-hydroxy esters and processes for their preparation from beta-keto esters and processes for the preparation of these beta-keto esters BAYER SCHERING PHARMA AG (DE) 2006-07-06 US disclosed
WO-2005064006-A1 OPTICALLY ACTIVE, HETEROAROMATIC β-HYDROXY ESTERS, PROCESSES FOR THEIR PREPARATION FROM β-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE β-KETO ESTERS SCHERING AKTIENGESELLSCHAFT (DE) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100248313-A1 NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS CYP8B1, HSD17B7, CYP51A1 CYP3A4 45/4885TDP1 3972/4885ALDH1A1 286/4885
US-20060148043-A1 Novel optically active, heteroaromatic beta-hydroxy esters and processes for their preparation from beta-keto esters and processes for the preparation of these beta-keto esters CYP8B1, HSD17B7, CYP51A1 CYP3A4 45/4885TDP1 3972/4885ALDH1A1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.